SABR for Early Non-Small Cell Lung Cancer: Changes in Pulmonary Function, Dyspnea, and Quality of Life

Ahn, J; Yeghiaian-Alvandi, R; Hegi-Johnson, F; Browne, LH; Graham, PH; Chin, Y; Gee, H; Vinod, S; Ludbrook, J; Last, A; Dwyer, P; Ong, A; Aherne, N; Azzi, M; Hau, E

Author(s): Ahn, J; Yeghiaian-Alvandi, R; Hegi-Johnson, F; Browne, LH; Graham, PH; Chin, Y; Gee, H; Vinod, S; Ludbrook, J; Last, A; Dwyer, P; Ong, A; Aherne, N; Azzi, M; Hau, E;
Details: Publication Year 2023-12-01,Volume 117,Issue #5,Page 1213-1221
Journal Title: International Journal of Radiation Oncology, Biology, Physics
Publication Type: Research article
Abstract: PURPOSE: The aim of this study was to report pulmonary function tests (PFTs) and clinician-reported and patient-reported quality-of-life (QoL) outcomes on a cohort of patients with non-small cell lung cancer (NSCLC) treated with SABR. METHODS AND MATERIALS: A total of 119 patients with NSCLC were treated with SABR in the prospective cohort SSBROC study of patients with T1-T2N0M0 NSCLC. PFTs and QoL measures were obtained at baseline pretreatment and at 6-month intervals. Here we report on the 6- to 18-month time points. Analysis of covariance (ANCOVA) methods adjusting for baseline analyzed potential predictors on outcomes of PFTs and patient-reported dyspnea at 18 months. RESULTS: The only statistically significant decline in PFTs was seen in forced expiratory volume in 1 second (FEV(1)) at 18 months post-SABR, with a decline of -0.11 L (P = .0087; 95% CI, -0.18 to -0.02). Of potential predictors of decline, only a 1-unit increase in smoking pack-years resulted in a -0.12 change in diffusing capacity for carbon monoxide (P = .026; 95% CI, -0.02 to -0.23) and a 0.003 decrease in FEV(1) (P = .026; 95% CI, -0.006 to -0.0004). For patient-reported outcomes, statistically significant worsening in both the European Organisation for Research and Treatment of Cancer Quality of Life Core Questionnaire (QLQ-C30 Version 3) and the lung module (QLQ-LC13) dyspnea scores occurred at the 18-month time point, but not earlier. No potential predictors of worsening dyspnea were statistically significant. There was no statistically significant decline in clinician-reported outcomes or global QoL scores. CONCLUSIONS: We found a statistically significant decline in FEV(1) at 18 months posttreatment. Smoking pack-years was a predictor for decline in diffusing capacity for carbon monoxide and FEV(1) at 18 months. Worsening of patient-reported dyspnea scores was observed, consistent with the expected progression of lung comorbid disease.
Publisher: Elsevier
Keywords: Humans; *Carcinoma, Non-Small-Cell Lung; *Lung Neoplasms; Quality of Life; Prospective Studies; Carbon Monoxide; Lung; Dyspnea/etiology
Department(s): Radiation Oncology
Publisher's Version: https://doi.org/10.1016/j.ijrobp.2023.07.017
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2024-01-16 04:49:17

Last Modified: 2024-07-09 04:59:27